<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399658</url>
  </required_header>
  <id_info>
    <org_study_id>11-098</org_study_id>
    <nct_id>NCT01399658</nct_id>
  </id_info>
  <brief_title>Image-Guided Gynecologic Brachytherapy</brief_title>
  <acronym>AMIGO</acronym>
  <official_title>A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard therapy for gynecologic cancers involves the use of brachytherapy, also called&#xD;
      internal radiation therapy or implant radiation. The treatment being studied consists of&#xD;
      standard brachytherapy with the additional use of MRI to guide the insertion of radioactive&#xD;
      applicators. The purpose of the study is to find out whether MRI-guided brachytherapy is&#xD;
      practical and beneficial when compared to the standard CT-guided brachytherapy placement. The&#xD;
      investigators are hoping that this MRI procedure will decrease the risk of giving too high a&#xD;
      radiation dose to the bladder or bowel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The insertion of the brachytherapy applicator will be administered in the Advanced&#xD;
      Multimodality Image-Guided Operating (AMIGO) suite at Brigham and Women's Hospital. Subjects&#xD;
      will undergo an MRI scan in the AMIGO suite ensuring proper placement of the applicator.&#xD;
      Subjects may have an optional FMISO-PET scan.&#xD;
&#xD;
      Subjects will have a follow-up visit including physical exam, pap smear, and MRI of the&#xD;
      pelvis and/or PET scan 90 days after treatment.&#xD;
&#xD;
      Subjects will have a follow-up visit including physical exam, pap smear, and MRI of the&#xD;
      pelvis and/or PET scan 180 days after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">March 2021</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose determination</measure>
    <time_frame>3 years</time_frame>
    <description>To determine doses to the rectum, sigmoid and bladder obtained after AMIGO-guided placement compared to standard CT-guided treatment with the anticipation that AMIGO-guided placement will result in lower OAR dosing than standard CT-based imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities: gastrointestinal, genitourinary, and skin</measure>
    <time_frame>3 years</time_frame>
    <description>To measure toxicities, including gastrointestinal, genitourinary, and skin, from physician-queries using the Common Toxicity Criteria for Adverse Events (CTCAE 4.0)&#xD;
To assess 90-day gastrointestinal, genitourinary, and skin toxicities and to compare AMIGO results to those obtained in prior CT and Magnetic Resonance Therapy (MRT) units.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Uterine Cancer</condition>
  <condition>Vaginal Cancer</condition>
  <condition>Carcinoma of the Vulva</condition>
  <arm_group>
    <arm_group_label>Image-Guided Brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Image-guided brachytherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Image-guided brachytherapy</intervention_name>
    <description>MRI-guided application of brachytherapy</description>
    <arm_group_label>Image-Guided Brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3'-Deoxy-3'-18f-Fluorothymidine</intervention_name>
    <description>Assessing tumor proliferation in Gynecologic cancer</description>
    <arm_group_label>Image-Guided Brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed carcinoma of the cervix (Stage I-IVA),&#xD;
             carcinoma of the uterus (Stage IIIB), carcinoma of the vagina (Stage I-IVA), or&#xD;
             carcinoma of the vulva (stage I-IVA)&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  MRI of the pelvis and/or PET-CT within 4 months prior to entering study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Pacemaker, brain aneurysm clip, inner ear implant, neurostimulator, or metal fragments&#xD;
             in the eye&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin King, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 8, 2011</study_first_submitted>
  <study_first_submitted_qc>July 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Martin King</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Brachytherapy</keyword>
  <keyword>Gynecological cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

